JP2015119705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015119705A5 JP2015119705A5 JP2014263739A JP2014263739A JP2015119705A5 JP 2015119705 A5 JP2015119705 A5 JP 2015119705A5 JP 2014263739 A JP2014263739 A JP 2014263739A JP 2014263739 A JP2014263739 A JP 2014263739A JP 2015119705 A5 JP2015119705 A5 JP 2015119705A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- dual target
- target antibody
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims 18
- 102000004965 antibodies Human genes 0.000 claims 18
- 230000027455 binding Effects 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 5
- 210000004027 cells Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100013180 KDR Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 3
- 238000003259 recombinant expression Methods 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 1
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 1
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100005175 CSF1R Human genes 0.000 claims 1
- 101700063802 CSF1R Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 102100010813 EGF Human genes 0.000 claims 1
- 101700033006 EGF Proteins 0.000 claims 1
- 101700041204 ERBB3 Proteins 0.000 claims 1
- 102000027776 ERBB3 Human genes 0.000 claims 1
- 101700023619 ERBB4 Proteins 0.000 claims 1
- 102100009851 ERBB4 Human genes 0.000 claims 1
- 210000002889 Endothelial Cells Anatomy 0.000 claims 1
- 101710003421 FGF Proteins 0.000 claims 1
- 108091008101 FGF receptors Proteins 0.000 claims 1
- 102100006565 FLT1 Human genes 0.000 claims 1
- 102100004573 FLT3 Human genes 0.000 claims 1
- 101710009074 FLT3 Proteins 0.000 claims 1
- 102100013182 FLT4 Human genes 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 102100014263 IGF1R Human genes 0.000 claims 1
- 101700025802 IGF1R Proteins 0.000 claims 1
- 108060003940 IL6 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000009029 Macular Degeneration, Age-Related, 2 Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 102100004939 PDGFRB Human genes 0.000 claims 1
- 101710018346 PDGFRB Proteins 0.000 claims 1
- 102100012897 PGF Human genes 0.000 claims 1
- 101710014083 PGF Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 229920002684 Sepharose Polymers 0.000 claims 1
- 210000002536 Stromal Cells Anatomy 0.000 claims 1
- 101710037124 TEK Proteins 0.000 claims 1
- 102100015249 VEGFA Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 1
- -1 c-Met Proteins 0.000 claims 1
- 101710014509 celF Proteins 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 210000002358 circulating endothelial cell Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 230000003511 endothelial Effects 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 102000017175 fibroblast growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 230000002489 hematologic Effects 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
Claims (18)
- 抗体の重鎖または軽鎖のN−末端に水溶性リガンドが融合された、二重標的抗体。
- 前記抗体が、腫瘍細胞、癌間質細胞、腫瘍関連内皮細胞、腫瘍関連内皮前駆細胞、腫瘍関連循環内皮細胞、循環腫瘍細胞および癌幹細胞からなる群より選ばれた細胞で特異的に発現する抗原に対する抗体である、請求項1に記載の二重標的抗体。
- 前記抗原が、VEGFR−1、VEGFR−2、VEGFR−3、FLT3、c−FMS/CSF1R、RET、c−Met、EGFR、Her2/neu、HER3、HER4、FGFR、IGFR、PDGFR、c−KIT、BCR、インテグリンおよびMMPからなる群より選択される、請求項2に記載の二重標的抗体。
- 前記抗体が、VEGFR−2/KDRに対する中和抗体TTAC0001である、請求項1に記載の二重標的抗体。
- 前記水溶性リガンドが、VEGF、EGF、PlGF、FGF、PDGF、HGFおよびアンジオポエチンからなる群より選択される、請求項1に記載の二重標的抗体。
- 前記水溶性リガンドが、アンジオポエチン2のTie−2に対する結合ドメインである、請求項1に記載の二重標的抗体。
- 前記水溶性リガンドが、リンカーを介して前記抗体の重鎖または軽鎖のN−末端に融合される、請求項1に記載の二重標的抗体。
- 請求項1から請求項7のいずれか一項に記載の二重標的抗体をコードする、DNA。
- 前記抗体の軽鎖および水溶性リガンドが、配列番号:6に示す塩基配列からなる、請求項8に記載のDNA。
- 請求項8に記載のDNAを含む、組換え発現ベクター。
- 図2に示す切断地図を有するpIgGLD−mAng2−TTAC0001 Lgtを含む、請求項10に記載の組換え発現ベクター。
- 請求項10に記載の組換え発現ベクターで形質転換された、宿主細胞。
- 請求項12に記載の宿主細胞を培養する段階;および
前記宿主細胞の培養液から二重標的抗体を単離する段階
を含む、二重標的抗体を製造する方法。 - 二重標的抗体が、プロテインA親和性カラム、SP−セファロースカラム、およびサイズ排除クロマトグラフィによる高速液体クロマトグラフィ(FPLC)を用いてさらに精製される、請求項13に記載の方法。
- 請求項1から請求項7のいずれか一項に記載の二重標的抗体を含む、薬学的組成物。
- 血管新生関連疾患の治療に用いられる、請求項15に記載の薬学的組成物。
- 血管新生関連疾患が、癌、老人性黄斑変性、関節リウマチ、糖尿病性網膜症、乾癬および慢性炎症からなる群より選択される、請求項16に記載の薬学的組成物。
- 癌が、胃癌、肝癌、肺癌、甲状腺癌、乳癌、子宮頸部癌、大腸癌、膵臓癌、直腸癌、結腸直腸癌、前立腺癌、腎臓癌、黒色腫、前立腺癌の骨転移癌、卵巣癌および血液癌からなる群より選択される、請求項17に記載の薬学的組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090044032A KR101224468B1 (ko) | 2009-05-20 | 2009-05-20 | 신규한 형태의 이중표적항체 및 그 용도 |
KR10-2009-0044032 | 2009-05-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012511742A Division JP5744012B2 (ja) | 2009-05-20 | 2009-07-22 | 新規な形態の二重標的抗体およびその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015119705A JP2015119705A (ja) | 2015-07-02 |
JP2015119705A5 true JP2015119705A5 (ja) | 2015-11-12 |
Family
ID=43126324
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012511742A Active JP5744012B2 (ja) | 2009-05-20 | 2009-07-22 | 新規な形態の二重標的抗体およびその使用 |
JP2014263739A Pending JP2015119705A (ja) | 2009-05-20 | 2014-12-26 | 新規な形態の二重標的抗体およびその使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012511742A Active JP5744012B2 (ja) | 2009-05-20 | 2009-07-22 | 新規な形態の二重標的抗体およびその使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10125194B2 (ja) |
EP (1) | EP2433968B1 (ja) |
JP (2) | JP5744012B2 (ja) |
KR (1) | KR101224468B1 (ja) |
CN (1) | CN102428104B (ja) |
AU (1) | AU2009346447B2 (ja) |
BR (1) | BRPI0924535B1 (ja) |
CA (1) | CA2762555C (ja) |
DK (1) | DK2433968T3 (ja) |
ES (1) | ES2605604T3 (ja) |
RU (1) | RU2520824C2 (ja) |
SG (1) | SG175971A1 (ja) |
WO (1) | WO2010134666A1 (ja) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2668210B1 (en) | 2011-01-26 | 2020-06-17 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
KR20120130658A (ko) * | 2011-05-23 | 2012-12-03 | 주식회사 파멥신 | 펩타이드가 융합된 이중표적항체 및 그 용도 |
CN108864291A (zh) | 2011-11-23 | 2018-11-23 | 拜奥文斯瑞有限公司 | 重组蛋白及其治疗用途 |
WO2013075740A1 (en) | 2011-11-23 | 2013-05-30 | Sanofi | Antibody purification method |
AU2013295848B2 (en) | 2012-07-25 | 2018-05-24 | Celldex Therapeutics, Inc. | Anti-KIT antibodies and uses thereof |
CA2892193C (en) * | 2012-11-21 | 2018-06-19 | Pharmabcine Inc. | Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same |
WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
KR102049991B1 (ko) | 2013-03-28 | 2019-12-02 | 삼성전자주식회사 | 항 c-Met/항 Her2 이중 특이 항체 |
KR102074421B1 (ko) | 2013-03-29 | 2020-02-10 | 삼성전자주식회사 | 항 c-Met/항 EGFR 이중 특이 항체 |
KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
JP6463734B2 (ja) * | 2013-05-06 | 2019-02-06 | サノフイSanofi | 抗体を精製するための連続的多工程法 |
KR20150063728A (ko) * | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-C/항 Ang2 이중 특이 항체 |
KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
AR100271A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Compuestos de vegfr2 / ang2 |
CN106659782B (zh) | 2014-05-23 | 2021-11-09 | 塞尔德克斯医疗公司 | 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体 |
KR20160024639A (ko) | 2014-08-26 | 2016-03-07 | 삼성전자주식회사 | c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF |
WO2016060297A1 (ko) * | 2014-10-16 | 2016-04-21 | 주식회사 파멥신 | VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체 |
KR102309881B1 (ko) | 2014-11-21 | 2021-10-06 | 삼성전자주식회사 | c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물 |
IL256562B1 (en) | 2015-07-15 | 2024-03-01 | Genmab As | Human CD3 antibodies or chimeras |
BR112019000512A2 (pt) | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
US20190309074A1 (en) * | 2016-09-08 | 2019-10-10 | Woori Technologies Corporation | Deglycosylated antibody specifically binding to clec14a and uses thereof |
EP3592769B1 (en) | 2017-03-09 | 2024-05-08 | Genmab A/S | Antibodies against pd-l1 |
CA3057907A1 (en) | 2017-03-31 | 2018-10-04 | Genmab Holding B.V. | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
AU2019237774B2 (en) * | 2018-03-19 | 2023-03-23 | Pharmabcine Inc | Anti-VEGFR-2 antibody |
CN111902720A (zh) | 2018-03-21 | 2020-11-06 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
US20210371525A1 (en) | 2018-09-19 | 2021-12-02 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
KR20210116429A (ko) | 2018-10-04 | 2021-09-27 | 젠맵 홀딩 비.브이. | 이중특이적 항-cd37 항체를 포함하는 제약 조성물 |
JP2022512875A (ja) | 2018-11-06 | 2022-02-07 | ゲンマブ エー/エス | 抗体製剤 |
NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
WO2020159368A1 (en) | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
BR112021021057A2 (pt) * | 2019-08-14 | 2021-12-14 | Pharmabcine Inc | Anticorpo anti-tie2 e uso do mesmo |
EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
AR121599A1 (es) | 2020-03-18 | 2022-06-22 | Genmab As | Anticuerpos |
EP4178981A1 (en) | 2020-07-08 | 2023-05-17 | LAVA Therapeutics N.V. | Antibodies that bind psma and gamma-delta t cell receptors |
JP2023536340A (ja) | 2020-08-06 | 2023-08-24 | ビオンテック・ソシエタス・エウロパエア | コロナウイルスsタンパク質のための結合剤 |
CA3190349A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
IL301085A (en) | 2020-09-10 | 2023-05-01 | Genmab As | A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma |
CA3200826A1 (en) | 2020-12-10 | 2022-06-16 | Paul Willem Henri Ida PARREN | Antibodies that bind gamma-delta t cell receptors |
EP4298125A1 (en) | 2021-02-26 | 2024-01-03 | LAVA Therapeutics N.V. | Antibodies that bind cd123 and gamma-delta t cell receptors |
CA3214582A1 (en) | 2021-05-07 | 2022-11-10 | Martin SAHLIN | Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3 |
EP4359435A1 (en) | 2021-06-21 | 2024-05-01 | Genmab A/S | Combination dosage regime of cd137 and pd-l1 binding agents |
WO2023037333A1 (en) | 2021-09-13 | 2023-03-16 | Janssen Biotech, Inc | CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
TW202330610A (zh) | 2021-10-08 | 2023-08-01 | 丹麥商珍美寶股份有限公司 | 結合至cd30及cd3之抗體 |
WO2023067138A1 (en) | 2021-10-21 | 2023-04-27 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1993023550A2 (en) | 1992-05-18 | 1993-11-25 | Genentech, Inc. | Activation of oligomerizing receptors by using fused receptor ligands |
US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
KR100816572B1 (ko) * | 1999-04-28 | 2008-03-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-vegf 항체 및 이를 포함하는 약제학적 조성물 |
US7090843B1 (en) * | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
AU2003213687A1 (en) | 2002-03-04 | 2003-09-22 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
CA2482607C (en) * | 2002-04-22 | 2013-06-11 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi |
EP1601697B1 (en) | 2003-02-28 | 2007-05-30 | Lonza Biologics plc | Antibody purification by Protein A and ion exchange chromatography |
JP4635255B2 (ja) | 2003-09-02 | 2011-02-23 | 独立行政法人産業技術総合研究所 | 抗体医薬 |
CN100503640C (zh) * | 2004-07-08 | 2009-06-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗肿瘤融合蛋白及其编码基因与应用 |
WO2006005361A1 (en) * | 2004-07-13 | 2006-01-19 | Centre National De La Recherche Scientifique | Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
CN1884300A (zh) * | 2005-06-24 | 2006-12-27 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种具有靶向功能的抗肝癌超抗原,其制备方法及用途 |
WO2008090958A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | ドメイン交換された遺伝子組換え抗体組成物 |
KR100883430B1 (ko) * | 2007-06-13 | 2009-02-12 | 한국생명공학연구원 | 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도 |
KR102060540B1 (ko) * | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
-
2009
- 2009-05-20 KR KR1020090044032A patent/KR101224468B1/ko active IP Right Grant
- 2009-07-22 SG SG2011082542A patent/SG175971A1/en unknown
- 2009-07-22 WO PCT/KR2009/004084 patent/WO2010134666A1/ko active Application Filing
- 2009-07-22 AU AU2009346447A patent/AU2009346447B2/en active Active
- 2009-07-22 CN CN200980159382.XA patent/CN102428104B/zh active Active
- 2009-07-22 BR BRPI0924535-9A patent/BRPI0924535B1/pt active IP Right Grant
- 2009-07-22 ES ES09844974.7T patent/ES2605604T3/es active Active
- 2009-07-22 RU RU2011146088/10A patent/RU2520824C2/ru active
- 2009-07-22 CA CA2762555A patent/CA2762555C/en active Active
- 2009-07-22 DK DK09844974.7T patent/DK2433968T3/en active
- 2009-07-22 EP EP09844974.7A patent/EP2433968B1/en active Active
- 2009-07-22 JP JP2012511742A patent/JP5744012B2/ja active Active
- 2009-07-22 US US13/319,899 patent/US10125194B2/en active Active
-
2014
- 2014-12-26 JP JP2014263739A patent/JP2015119705A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015119705A5 (ja) | ||
RU2011146088A (ru) | Антитело двойной направленности в новой форме и его применение | |
RU2509085C2 (ru) | Стабилизированные антитела против ангиопоэтина-2 и их применение | |
CL2016002116A1 (es) | Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13). | |
JP2015516801A5 (ja) | ||
JP2011510632A5 (ja) | ||
PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
RU2018111390A (ru) | Фармацевтическая композиция, содержащая в качестве активного ингредиента слитый белок, в котором слиты проникающий в опухоль пептид и антиангиогенное средство, для предупреждения и лечения рака или связанных с ангиогенезом заболеваний | |
CY1125797T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπευτικη αντιμετωπιση του καρκινου | |
CL2011003182A1 (es) | Anticuerpo anti-vegf o fragmento de union del mismo que comprende cdrs con secuencias aminoacidicas con hasta 17 mutaciones respecto a las secuencias cdrs del anticuerpo bavacizumab o ranibizumab; acido nucleico; vector; celula huesped; metodo de produccion; conjugado anticuerpo-farmaco; composicion; y uso para tratar cancer. | |
EA201591515A1 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение | |
EA201891641A1 (ru) | Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста | |
CY1118608T1 (el) | Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6 | |
CN107207574A (zh) | 血管生成特异性的新型蛋白 | |
UA118096C2 (uk) | ВИДІЛЕНА БІСПЕЦИФІЧНА МОЛЕКУЛА, ЩО ЗВ'ЯЗУЄТЬСЯ З ДОМЕНОМ ФІБРОНЕКТИНУ ІІІ ТИПУ EGFR I c-Met | |
EA200970700A1 (ru) | Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний | |
EP2579895A4 (en) | ANTI-VEGF ANTIBODIES AND USES THEREOF | |
PE20080352A1 (es) | COMPOSICIONES QUE COMPRENDEN ANTICUERPOS DE c-Met | |
EA201390738A1 (ru) | Нейтрализующие антитела против ccl20 | |
EA202091198A1 (ru) | Полипептиды, содержащие домен d, и их применение | |
WO2013036232A3 (en) | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases | |
He et al. | A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging | |
HRP20120828T1 (hr) | Cjepivo | |
CL2016000438A1 (es) | Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica | |
EA201401065A1 (ru) | Ang2-связывающие молекулы |